Drugs / Amino Acid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07212595 | Jul 2026 → Nov 2027 expected | acute kidney injury | Dana Fuhrman | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02926235 | Apr 2016 → May 2022 | muscular atrophy | Hospital for Special Surgery, New York | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04785170 | Feb → Mar 2021 | — | Vedic Lifesciences Pvt. Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00313807 Comparator | Nov 2005 → Sep 2008 | kidney failure | Queen's University | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04695613 Comparator | Jan → Mar 2021 | benign shuddering attacks | Assiut University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amino Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02926235 ↗ |
| Modality | Other / unclassified | “A novel non-protein amino acid secreted by skeletal muscles” NCT04785170 ↗ |
| Route | Intravenous | “intravenous amino acid infusion” NCT00313807 ↗ |